Last Updated on October 14, 2024 by
The U.S. Food and Drug Administration (USFDA) approved drugs from AbbVie Inc. and Pfizer Inc. for treating eczema, a skin disease, the companies said on Friday.
AbbVie’s Rinvoq and Pfizer’s Cibinqo have been approved to treat moderate-to-severe atopic dermatitis, or eczema, in patients who do not respond to previous treatments or when use of other treatments is not recommended.
Rinvoq’s approval was expanded from rheumatoid arthritis to treat eczema for patients 12 years and older, while Cibinqo was approved for use in only adults.
Both the drugs belong to a class called JAK inhibitors, which block inflammation-causing enzymes known as Janus kinases and target a range of autoimmune diseases.
Both Pfizer and AbbVie cited risks of serious infections and cardiovascular events, among others.
The expanded approval for Rinvoq follows significant delays amid concerns over safety of JAK inhibitors.
Cibinqo had last year received approvals from the European and UK regulators.
The USFDA last month added its strictest warning to labels of JAK inhibitor drugs from Pfizer, Eli Lilly and AbbVie following a review of Pfizer’s Xeljanz, another JAK inhibitor.
The initial results from a trial showed an increased risk of serious heart-related problems and cancer in some patients being treated with the drug.
USFDA gives nod to Glenmark for Nasal Spray to treat allergic rhinitis
USFDA gives tentative nod to Alembic for Dronedarone tablets
USFDA gives nod to Alembic Pharma for Vortioxetine tablets
USFDA gives nod to Alembic for generic drug to treat Parkinsonโs disease
USFDA gives nod to Alembic Pharma for Doxycycline Hyclate tablets
USFDA gives tentative nod to Zydus Cadila for Pimavanserin capsules
Kerala DCA writes to NPPA to bring Kidney drug under DPCO
Pharma firms to install PNG run boilers to improve Air quality
Full marketing approval sought from DCGI for Covaxin
USFDA gives nod to Glenmark for Nasal Spray to treat allergic..
Narcotic Control Bureau seizes Drugs worth Rs 30 lakh
Big Pharma Companies buying land in Hyderabad
Govt warns against overuse, misuse of COVID medicines
BIS notifies new standard for these Medical Devices
Latest Notifications: Medical Devices
Latest Notifications regarding Pharmaceuticals
